Jitka Fucikova, Lenka Palova-Jelinkova, Vanessa Klapp, Peter Holicek, Tereza Lanickova, Lenka Kasikova, Jana Drozenova, David Cibula, Beatriz Álvarez-Abril, Elena García-Martínez, Radek Spisek, Lorenzo Galluzzi. Trends in Cancer. 2022 February 15. doi.org/10.1016/j.trecan.2022.01.010. IF: 14,226
doc. PharmDr. Jitka Palich Fučíková, Ph.D., Ústav imunologie 2. LF UK a FN Motol
Epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitor (ICI)-based immunotherapy, largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Various agents routinely used for clinical EOC management mediate therapeutically relevant immunostimulatory or immunosuppressive effects.
Preclinical data indicate that these therapeutics stand out as promising partners for ICI-based immunotherapy in models of EOC. Clinical evidence in support of this paradigm remains scant, pointing to various, hitherto unresolved, challenges.
At odds with other solid tumors, epithelial ovarian cancer (EOC) is poorly sensitive to immune checkpoint inhibitors (ICIs), largely reflecting active immunosuppression despite CD8+ T cell infiltration at baseline. Accumulating evidence indicates that both conventional chemotherapeutics and targeted anticancer agents commonly used in the clinical management of EOC not only mediate a cytostatic and cytotoxic activity against malignant cells, but also drive therapeutically relevant immunostimulatory or immunosuppressive effects. Here, we discuss such an immunomodulatory activity, with a specific focus on molecular and cellular pathways that can be harnessed to develop superior combinatorial regimens for clinical EOC care.